Search

Liposomal-amphotericin B (L-AmB) is used for cutaneous leishmaniasis (CL); however, its treatment failure has not yet been described in detail. A 58-year-old man returned from the Republic of Venezuela with a cutaneous ulcer on his left lower leg. The causative pathogen was Leishmania braziliensis. We started L-AmB 3 mg/kg/day for 6 days; however, the ulcer did not resolve. The patient was successfully retreated with a higher dose L-AmB 4 mg/kg/day 9 times (total, 36 mg/kg). If L-AmB fails to treat CL and other therapeutics cannot be used, increasing the L-AmB dose is a viable option.

Let $\mathbb{S}^N\subset\mathbb{R}^{N+1}$, $N\ge 3$, be the unit sphere, and let $S_{\Theta}\subset\mathbb{S}^N$ be a geodesic ball with geodesic radius $\Theta\in(0,\pi)$. We study the bifurcation diagram $\{(\Theta,\left\|U\right\|_{\infty})\}\subset\mathbb{R}^2$ of the radial solutions of the Emden-Fowler equation on $S_{\Theta}$ $\Delta_{\mathbb{S}^N}U+U^p=0$ in $S_{\Theta}$, $U=0$ on $\partial S_{\Theta}$, $U>0$ in $S_{\Theta}$, where $p>1$. Among other things, we prove the following: For each $p>p_{\rm S}:=(N-2)/(N+2)$, there exists $\underline{\Theta}\in(0,\pi)$ such that the problem has a radial solution for $\Theta\in(\underline{\Theta},\pi)$ and has no radial solution for $\Theta\in(0,\underline{\Theta})$. Moreover, this solution is unique in the space of radial functions if $\Theta$ is close to $\pi$. If $p_{\rm S}

Publication in the conference proceedings of EUSIPCO, Viena, Austria, 2004

Purpose: The purpose of this study is to compare response rates of lenvatinib and atezolizumab plus bevacizumab, in first-line real-world setting. Methods: Overall cohort included Western and Eastern hepatocellular carcinoma (HCC) patient populations from 46 centres in 4 countries (Italy, Germany, Japan, and Republic of Korea). Results: 1312 patients were treated with lenvatinib, and 823 patients were treated with atezolizumab plus bevacizumab. Objective response rate (ORR) was 38.6% for patients receiving lenvatinib, and 27.3% for patients receiving atezolizumab plus bevacizumab (p < 0.01; odds ratio 0.60). For patients who achieved complete response (CR), overall survival (OS) was not reached in both arms, but the result from univariate Cox regression model showed 62% reduction of death risk for patients treated with atezolizumab plus bevacizumab (p = 0.05). In all multivariate analyses, treatment arm was not found to be an independent factor conditioning OS. Comparing ORR achieved in the two arms, there was a statistically significant difference in favor of lenvatinib compared to atezolizumab plus bevacizumab in all subgroups except for Eastern patients, Child-Pugh B patients, presence of portal vein thrombosis, α-feto-protein ≥ 400 ng/mL, presence of extrahepatic disease, albumin-bilirubin (ALBI) grade 2, and no previous locoregional procedures. Conclusion: Lenvatinib achieves higher ORR in all patient subgroups. Patients who achieve CR with atezolizumab plus bevacizumab can achieve OS so far never recorded in HCC patients. This study did not highlight any factors that could identify patient subgroups capable of obtaining CR.